Skip to main content

Table 3 Antigen specific T cell responses

From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

Patient Number

Peak 5T4 polyclonal precursor frequencies

ORR (month)

 

Time point (week)

Peptides alone

Time Point (week)

Protein + Peptides

 

1

-

< 1/200,000

-

< 1/200,000

PD

2

-

< 1/200,000

3

1/19,231

PD

3

-

< 1/200,000

-

< 1/200,000

PD

5

55

1/12,048

55

1/1,701

Surgical CR(50+)

6

26

1/21,277

26

1/21,277

SD (13)

7

29

1/2,113

29

1/2,113

SD (9)

8

-

< 1/200,000

-

< 1/200,000

PD

9

105

1/993

105

1/993

Surgical CR(54+)

10

-

< 1/200,000

-

< 1/200,000

PD

11

-

< 1/200,000

9

1/12,500

SD (2)

12

-

< 1/200,000

-

< 1/200,000

PD

13

15

1/11,765

15

1/11,765

SD (1)

14

-

< 1/200,000

-

< 1/200,000

PD

15

-

< 1/200,000

92

1/19,231

SD (18)

16

-

< 1/200,000

-

< 1/200,000

SD (2)

17

78

1/7,042

78

1/4,132

SD (16)

19

-

< 1/200,000

20

1/20,833

SD (5)

20

-

< 1/200,000

-

< 1/200,000

PD

21

-

< 1/200,000

-

< 1/200,000

PD

22

9

1/12,821

9

1/12,821

PD

23

-

< 1/200,000

-

< 1/200,000

Surgical CR (13+)

24

-

< 1/200,000

6

1/12,048

SD (3.5)

25

-

< 1/200,000

3

1/18,868

PD

  1. The peak 5T4 specific responses detected at any time point to 5T4 peptides or 5T4 peptide plus protein. *; no detection of 5T4 responses. Positive responses are indicated as bold type.